Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: Midazolam, Imlunestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Interventions: Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells; Diagnostic Test · Genetic · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 0 Years to 99 Years
Enrollment: 50 participants
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy, PK Drug-drug Interaction Study
Interventions: Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride; Drug
Lead sponsor: Quivive Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Post-Traumatic Stress Disorder, Acute Respiratory Failure
Interventions: Ketamine, Etomidate; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 3 more

Conditions: The Focus of This Study Are New Pulse Sequences.
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastro Esophageal Reflux
Interventions: ARAT, Sham intervention (control); Procedure
Lead sponsor: Midwest Veterans' Biomedical Research Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Idiopathic Intracranial Hypertension
Interventions: MR elastography, MRI structural brain imaging, Lumbar puncture, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound; Diagnostic Test · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Astigmatism
Interventions: 1-DAY ACUVUE® MOIST contact lenses, 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses, No contact lenses; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 39 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 89 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Autism
Interventions: Early Start Denver Model (ESDM), Early Intensive Behavioral Intervention (EIBI); Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Months and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Vigil, Atezolizumab; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more

Conditions: Treatment Resistant Depression
Interventions: CERC-501, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: SID530, Taxotere; Drug
Lead sponsor: SK Chemicals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Canton, Ohio

Conditions: Kidney Failure
Interventions: Balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: GSK1349572; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Palbociclib Alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Miami, Florida • South Miami, Florida

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Onychomycosis
Interventions: Albaconazole tablet 400mg, Albaconazole 100mg capsules, then albaconazole 400mg tablet; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obesity / Overweight
Interventions: Pistachio Co-consumption, Refined-Carbohydrate Control Co-consumption; Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Post-traumatic Stress Disorder (PTSD), Trauma and Stress Related Disorders, Occupational Stress, Emotional Regulation Difficulties, Anger Problems, Relational Problems, Irritability
Interventions: Brazilian Jiu-Jitsu Program; Behavioral
Lead sponsor: Sam Houston State University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Conroe, Texas

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Inflammatory Response
Interventions: 44-Day Diet Conventionally Sourced - YELLOW Diet, 44-Day Diet Agro-Ecologically Sourced - GREEN Diet; Other
Lead sponsor: Utah State University; Other
Eligibility: 35 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions: 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Study of Imlunestrant (LY3484356) in Healthy Women

Baker Gordon Syndrome Natural History Study

Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension

Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

Clinical Testing of New MR Pulse Sequences

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

Evaluating Raised Intracranial Pressure Using MR Elastography

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism

Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate

Advanced MRI Sequences for Radiation Therapy Treatment Planning

Examining the Effectiveness of the Early Start Denver Model in Community Programs Serving Young Autism

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Study to Evaluate SID 530 Compared to Taxotere

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

GSK1349572 Drug Interaction Study With Protease Inhibitors

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or Obesity

Grappling With Trauma: Brazilian Jiu-Jitsu for First Responders

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

The Effects of Agro-ecological Farming Systems on Human Health

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors